Citations

Clear

9383 citation(s) found for "Thomas, PS".

Left atrial appendage occlusion in patients with end-stage renal disease: an individual patient-level meta-analysis
Rodriguez, Juan F. , Vemulapalli, Hema Srikanth , Akın, İbrahim , Areiza, Luis A , Rocca, Domenico G. Della , Eitel, Ingo , Fink, Thomas , Genovesi, Simonetta , Kefer, Joëlle , Prajapati, Poojan , Srivathsan, Komandoor , Rodriguez-Riascos, Juan F , Vemulapalli, Hema S , Della Rocca, Domenico G , Zweiker, David , Prajapati, Poojan , Srivathsan, Komandoor

Mayo Clinic

Europace | August 28, 2025 | Volume: 27 | Issue: 10 | Pages: No page available

10.1093/europace/euaf198 | PMID 40879386 Get It

Abstract Aims Patients with end-stage renal disease (ESRD) and atrial fibrillation present a challenge for thromboembolic prevention, given their elevated risks of both thromboembolism and bleeding. Anticoagulants carry a higher bleeding risk in this population without clear evidence of thromboembolic benefit. This study aims to define the role of left atrial appendage occlusion (LAAO) as a preventive strategy for patients with ESRD. Methods and results A systematic literature review was conducted to identify studies reporting outcomes in patients with ESRD who underwent LAAO. Meta-analyses of aggregate and individual patient data were performed to evaluate acute and long-term outcomes and compare them with those of patients without ESRD. Seventeen studies reporting data from 24 127 patients, including 1047 with ESRD, were included. Procedural complications were more common in patients with ESRD (RR 2.23; P = 0.02), with a pooled rate of 4% (95% CI, 1–9%). There was no significant difference in thromboembolic event rates during follow-up between the groups (IRR 1.44; P = 0.16), but major bleeding incidence was higher among patients with ESRD (IRR 1.84; P < 0.01). Individual patient-level data from seven studies comprising 4745 patients (268 with ESRD) were obtained and analysed. Similarly, there was no significant association between ESRD and stroke/TIA incidence (HR, 1.22; 95% CI, 0.66–2.26), but major bleeding was higher on patients with ESRD (HR, 1.65; 95% CI, 1.01–2.69). Conclusion LAAO represents a feasible option for thromboembolic prevention in patients with ESRD, although these patients have an increased risk of complications and bleeding.
Conventional versus advanced imaging selection for endovascular treatment of basilar artery occlusion strokes
Chen, Huanwen , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Grossberg, Jonathan A , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Mascitelli, Justin, Fragata, Isabel , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Matouk, Charles, Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Dağlıoğlu, Ergün , Williamson, Richard , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Kan, Peter , Maier, Ilko , Jabbour, Pascal , Samaniego, Edgar A , Crosa, Roberto , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Fragata, Isabel , Colasurdo, Marco , Matsukawa, Hidetoshi , Cunningham, Conor M. , Kasab, Sami Al , Goyal, Nitin , Cuellar, Hugo, Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Osbun, Joshua W , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De , Chen, Huanwen

Mayo Clinic

European Stroke Journal | August 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/23969873251364973 | PMID 40873294 Get It

Introduction: Endovascular thrombectomy (EVT) is an effective treatment for basilar artery occlusion (BAO) stroke in select patients. While there is a growing body of literature suggesting that advanced imaging modalities such as computed tomography perfusion (CTP) and magnetic resonance (MR) may not be necessary for selecting anterior circulation large vessel occlusion stroke patients for EVT, whether advanced imaging may be superior to conventional imaging (non-contrast CT and CT angiography) in identifying good treatment candidates among BAO patients is less clear. Patients and methods: This was a multicenter retrospective cohort study of BAO EVT patients treated from 2013 to 2022 in the Stroke Thrombectomy and Aneurysm Registry. Patients selected for EVT by advanced imaging (CTP or MR) were matched with those selected by conventional imaging using propensity score matching (PSM) accounting for possible confounders. Primary outcome was functional independence at 90 days. Other outcomes include bedridden state or death at 90-days and symptomatic intracranial hemorrhage (sICH). Results: 268 patients were included. 150 patients were selected for BAO EVT by conventional imaging, 86 by CTP, and 32 by MR. Patients selected by advanced imaging were significantly older than those selected by conventional imaging (median age 71 vs 64 years, p = 0.001); patient characteristics were otherwise similar between cohorts. After PSM, 90-day outcomes were similar between the two cohorts ( p = 0.56), with similar rates of functional independence (39.4% vs 35.1%, p = 0.65), bedridden state or death (40.4% vs 44.7%, p = 0.66), and sICH (3.3% vs 5.7%, p = 0.49) for conventional and advanced imaging groups, respectively. Results were similar across treatment time windows (all p > 0.05). Conclusions: Selecting patients for basilar EVT using conventional versus advanced imaging did not result in different clinical outcomes, regardless of treatment time windows. Conventional imaging appears sufficient as a first-line tool for selecting basilar EVT patients in routine clinical practice.
Sex and Age Differences in Exercise Frequency and Exercise Capacity After Home-Based Cardiac Rehabilitation During the Coronavirus Disease 2019 (COVID-19) Pandemic
Hama, Tomoaki , Chacin-Suarez, A, Bissen, Thomas G. , Shultz, Adam M. , Salstrand, Rosalyn M., Smith, Joshua R. , Bonikowske, Amanda R. , Olson, Thomas P. , Chacin-Suarez, Audry S, Smith, Joshua R

Mayo Clinic

Circulation Journal | August 26, 2025 | Volume: 89 | Issue: 10 | Pages: 1616-1626

10.1253/circj.cj-25-0227 | PMID 40866233 Get It

Safety and Efficacy Findings From a Phase Ib/ II Study of ASP ‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squ
Cognetti, David M. , Johnson, Jennifer M. , Kwon, Michael , Su, Shirley Y. , Civantos, Francisco , Valentino, Joseph, Bell, R. Bryan, Abel, Kathryn M. Van , Price, Katharine A. , Dong, Haiying, Thorne, Amy Haseley, Van Abel, Kathryn M , Su, Shirley Y , Curry, Joseph , Olazagasti, Coral , Arnold, Susanne M. , Gibson, Michael K. , Mannion, Kyle , Suzuki, Toshiaki , Gillenwater, Ann Marie

Mayo Clinic

Head & Neck | August 25, 2025 | Volume: 48 | Issue: 1 | Pages: 160-174

10.1002/hed.70014 | PMID 40852760 Get It

ABSTRACT Background ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing. Methods This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 combined positive score ≥ 1, ineligible for standard locoregional therapy). Primary objectives were safety/tolerability and objective response rate (ORR). Secondary objectives included overall survival (OS) and progression‐free survival (PFS). Results Eighteen patients (median age 63 years, 74% male) comprised the photoimmunotherapy‐evaluable population. The confirmed ORR was 27.8% (95% CI 9.7–53.5); four of five responders had complete responses (95% CI, 6.4–47.6). Median OS was 25.6 months (95% CI, 14.6–not evaluable); median PFS was 2.9 months (95% CI, 1.4–14.6). The most common serious adverse reactions were dysphagia and tongue edema (each n = 2; 10.5%). Conclusions ASP‐1929 photoimmunotherapy plus pembrolizumab was generally tolerable, with promising efficacy in patients with recurrent/metastatic HNSCC.
Genetic and Cellular Architecture of Breast Cancer Risk Across Ancestries
Zanti, Maria , Williams, Jacob , Jahagirdar, Om , Turcan, Alistair, Brandenburg, Jean‐Tristan , Li, Jingmei, Miranda, Patricio , Godbole, Devika , Zhang, Xiaomeng , Dorling, Leila , Dennis, Joe, John, Esther M. , Kushi, Lawrence H., Carvajal‐Carmona, Luis G. , Haiman, Christopher A. , Ziv, Elad , Easton, Douglas F. , Chanock, Stephen J., Chatterjee, Nilanjan , Kraft, Peter, Wong, Wendy S W , Zhu, Qianqian , Ahearn, Thomas U., Li, Jingmei , Zhang, Haoyu , John, Esther M , Li, Jingmei , Ziv, Elad , Li, James , Jia, Guochong , Hu, Qiang , Li, Yàn , Ho, Weang-Kee , Dias, Julie‐Alexia , Chen, Wenlong Carl , Boddicker, Nicholas , Wang, Ying , Martin, Alicia R. , Zhang, Yan , Torres-Mejı́a, Gabriela , Kushi, Lawrence H, Weitzel, Jeffrey N. , Neuhausen, Susan L. , Fejerman, Laura , Zheng, Wei , Huo, Dezheng , Chanock, Stephen Jacob , Chatterjee, Nilanjan , García‐Closas, Montserrat , Michailidou, Kyriaki , Zhang, Martin Jinye , Dutta, Diptavo , Ahearn, Thomas U.

Mayo Clinic

No container title available | August 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.20.25334075 | PMID 40909829 Get It

Abstract Background Breast cancer genome-wide association studies (GWAS) have identified more than 200 susceptibility loci, but most studies are dominated by European and East Asian populations. Methods We analyzed breast cancer GWAS summary statistics from African (AFR), East Asian (EAS), European (EUR), and Hispanic/Latina (H/L) samples (159,297 cases and 212,102 controls). We estimated logit-scale SNP-based heritability, polygenicity, and cross-ancestry genetic correlation, partitioned heritability across functional annotations, and integrated GWAS results with the Tabula Sapiens single-cell atlas using scDRS+. Results The logit-scale heritability of breast cancer ranged from ℎ 2 =0.47 (SE = 0.07) in EAS to AFR ℎ 2 =0.61 (SE = 0.10), with no significant differences across ancestries (p=0.63). The estimated number of susceptibility markers in a sparse normal-mixture effects model also varied from 4,446 (SE = 3,100) in EAS to 8,308 (SE = 2,751) in AFR, but differences were not significant across ancestries (p=0.55). Cross-sample genetic correlations varied, with the strongest correlation between EUR and EAS (𝜌 = 0.79, SE = 0.08) and weakest between AFR and H/L (𝜌 = 0.26, SE = 0.24). Regulatory annotations were enriched for breast cancer heritability across samples. Integration with single-cell expression profiles implicated ancestry-shared associations with innate immune, secretory epithelial, and stromal cell types. Conclusion These results indicate substantial cross-ancestry sharing of breast cancer polygenic architecture, highlight a consistent contribution of regulatory variation, and identify convergent cellular contexts that motivate functional follow-up and inform expectations for the transferability and attainable performance of common-variant risk prediction across populations.
Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial
Merry, Stephen , Brennan, David N. , Duvall, Michelle J., Stanek, J., O’Dowd, Erin, Thacher, Tom D. , Merry, Stephen P , Duvall, Michelle , Stanek, Joseph B , O'Dowd, Erin K , Thacher, Thomas D

Mayo Clinic

Journal of Primary Care & Community Health | August 23, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251365853 | PMID 40847834 Get It

Introduction: Treatment of cutaneous warts with intralesional vitamin D3 has demonstrated promising results in over 35 studies with methodological limitations. Methods: We conducted a randomized, double-blind, placebo-controlled trial in our primary care procedure clinic of intralesional vitamin D3 12 000 IU vs placebo in cutaneous warts every 4 weeks up to 3 times. Warts were assessed 4, 8, 12, and 24 weeks after the initial injection. The primary outcome was complete wart resolution. Reduction in wart size was a secondary outcome. Results: Between October 2020 and April 2023, we enrolled 77 participants with 1 or more cutaneous warts (41 and 36 in vitamin D3 and placebo groups, respectively) with untreated (32%) and recalcitrant (69%) warts. At 24 weeks, the index wart had resolved in 12 (30%) of vitamin D3 and 10 (31%) placebo participants. Treatment with vitamin D3 had no effect on wart surface area in an adjusted model nor wart resolution in analysis adjusted for baseline wart size, multiple warts, and the vehicle (OR 0.31 [95% CI] 0.01-10.3; P = 0.51). Conclusions: These results demonstrate a lack of benefit of intralesional vitamin D3 in cutaneous warts. ( ClinicalTrials.gov number NCT04278573)
External Validation of a Multivariable Diagnostic Prediction Model for Acute Invasive Fungal Rhinosinusitis in Tertiary Care Settings
Ellefson, Johanna L. , Yang, Qiuyu , Stokken, Janalee K., Pasic, Thomas R., Koszewski, Ian J., Lin, Sandra Y. , Stokken, Janalee K. , Yin, Linda X , Carlson, Matthew L , Spillinger, Aviv , Yin, Linda X.

Mayo Clinic

International Forum of Allergy & Rhinology | August 23, 2025 | Volume: 16 | Issue: 1 | Pages: 16-22

10.1002/alr.70024 | PMID 40847590 Get It

ABSTRACT Background Prompt detection and intervention are crucial for improving outcomes in acute invasive fungal rhinosinusitis (AIFS). Diagnostic prediction models assist in risk‐stratification, but their accuracy requires testing through external validation. This study aims to validate a previously published diagnostic prediction model for AIFS in an independent cohort. Methods A retrospective chart review was conducted at a tertiary care center (2008–2023) to identify patients with an otolaryngology consult for suspected AIFS. Of 65 patients identified, 11 (16.9%) were diagnosed with AIFS based on histopathology. Risk was calculated using Yin et al.’s predictive model. Predictive performance was assessed by calibration and discrimination. Results Patients had significantly higher rates of diabetes (46.2% vs. 26.1%, p = 0.002), long‐term steroid use (60% vs. 28.2%, p < 0.0001), and solid organ transplantation (38.5% vs. 8.5%, p < 0.001), compared with the development cohort, with conversely lower rates of hematologic malignancy (29.2% vs. 58.7, p < 0.001) and neutropenia (19.4% vs. 41%, p = 0.001). Despite these differences, both the three‐variable (C‐index: 0.844; 95% CI, 0.736–0.952) and four‐variable models (C‐index: 0.963; 95% CI, 0.919–1) showed adequate discrimination. Both models exhibited slight overprediction of risk, with a calibration‐in‐the‐large predicted risk of 24.1% (95% CI, 13.68–34.46) for the three‐variable model and 24.2% (95% CI, 13.76–34.57) for the four‐variable model. Calibration plots confirmed overprediction. Conclusion The AIFS diagnostic model demonstrates acceptable discrimination and calibration on external validation, with generalizability to patients with different comorbidities. Larger studies are recommended to further test the model's predictive performance and clinical applicability.
Safety and efficacy of preoperative embolization in the treatment of brain arteriovenous malformations with perinidal aneurysms and single draining vein: a multicenter study with propensity score-weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Ogilvy, Christopher S. , Sheehan, Jason , Aslan, Assala , Patel, Pious D. , Lan, Matthews , Baldassari, Michael P. , Koduri, Sravanthi , Atallah, Elias , Zeineddine, Hussein A. , Pontarelli, Mary-Katharine , Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Başkaya, Mustafa K. , Ataoglu, Cagdas , Mccarthy, Finn, Sanchez‐Forteza, Anthony , Essibayi, Muhammed Amir , Muram, Sandeep , Sconzo, Daniel , Riina, Howard A. , Rezai, Arwin, Alwakaa, Omar , Erginoğlu, Ufuk , Sen, Rajeev , Devia, Diego A., Perez-Mendez, Wilfran, Puentes, Juan C. , Spiotta, Alejandro M , Puri, Ajit S , Singh, Jasmeet, Burkhardt, Jan Karl, Starke, Robert M., Sekhar, Laligam N., Haranhalli, Neil , McAvoy, Malia , Eltiti, Marah, Abushehab, Abdallah, Foreman, Paul M. , Zaidat, Osama O. , Ruppert-Gomez, Marcella , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M, Alshahrani, Rabab, Gooch, M Reid, Rosenwasser, Robert H. , Bulsara, Ketan R., Kan, Peter , Kim, Louis J. , Pukenas, Bryan , Li, Yan-Lin , Alaraj, Ali , Fuschi, Maurizio , Patel, Aman B. , Notarianni, Christina , Cuellar, Hugo H, Lawton, Michael T., Guthikonda, Bharat , Jabbour, Pascal , Salim, Hamza , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Ogilvy, Christopher S , Dmytriw, Adam A , Aslan, Assala , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Abo Kasem, Rahim , Spiotta, Alejandro M , Levitt, Michael R , Altschul, David J , Shakir, Hakeem J , Zaidat, Osama O , Stapleton, Christopher , Koch, Matthew J , Chen, Peng R , Kan, Peter , Choudhri, Omar , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Erginoglu, Ufuk , Li, Yan-Lin , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Kondziolka, Douglas , Dmytriw, Adam A. , Abou‐Al‐Shaar, Hussam , Naamani, Kareem El, Abdelsalam, Ahmed , Kumbhare, Deepak , Mccarthy, Finn, Keleş, Abdullah , Tos, Salem M , Mantziaris, Georgios , Park, Min S, Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Ocampo-Navia, María Isabel , Kasem, Rahim Abo , Kühn, Anna Luisa , Sekhar, Laligam N. , Levitt, Michael R. , Altschul, David , Almajali, Mohammad , See, Alfred P. , Abla, Adib A. , Patel, Aashay , Nguyen, Andrew , Srinivasan, Visish M. , Blackburn, Spiros , Gooch, Michael Reid , Kim, Louis J. , Choudhri, Omar , Simonato, Davide , Savardekar, Amey Rajan , Lawton, Michael T. , Morcos, Jacques J.

Mayo Clinic

Journal of NeuroInterventional Surgery | August 22, 2025 | Volume: 18 | Issue: 8 | Pages: 1765-1772

10.1136/jnis-2025-023873 | PMID 40846482 Get It

Background and objectives Arteriovenous malformations (AVMs) with perinidal aneurysms and single draining vein are associated with an elevated risk of rupture and increased procedural complexity. The role of preoperative embolization in this high-risk anatomical subset remains unclear. This study aimed to evaluate the safety and efficacy of microsurgery with preoperative embolization, compared with microsurgery alone in patients with such AVMs. Methods We conducted a multicenter retrospective analysis of an AVM registry from the MISTA (Multicenter International Study for Treatment of Brain AVMs) consortium and included AVMs with perinidal aneurysms and a single draining vein. Baseline characteristics, angiographic outcomes, functional outcomes, and complication rates were compared. Propensity score weighting (PSW) using the covariate balancing method was applied to adjust for baseline differences. Results Out of a total of 1919 patients, 65 met the inclusion criteria; 45 patients underwent preoperative embolization followed by microsurgery, and 20 underwent microsurgery alone. After adjustment, complete obliteration rates were similar between groups (OR 0.87, 95% CI 0.04 to 16.33, P=0.92), as were rates of functional independence at discharge and follow-up. Overall complication, symptomatic complication, and mortality rates did not differ significantly between groups. However, permanent complications were significantly lower in patients with preoperative embolization (OR 0.06, 95% CI 0.004 to 0.84, P=0.03). Discussion In patients with AVMs featuring perinidal aneurysms and single draining vein, preoperative embolization followed by microsurgery was associated with fewer permanent complications and no increase in adverse outcomes compared with microsurgery alone. However, given the small number of events, this finding should be interpreted cautiously.
Serious Illness Conversation in the Care of Atypical Parkinsonian Disorders: A Practical Guide for Neurology Clinicians
Bruno, Michiko Kimura , Jiao, Jocelyn , Kramer, Neha M. , Ivancic, Margaret , Chou, Claudia , Shurer, Jessica , Carroll, Thomas , Bruno, Michiko K

Mayo Clinic

Movement Disorders Clinical Practice | August 22, 2025 | Volume: 13 | Issue: 2 | Pages: 344-358

10.1002/mdc3.70300 | PMID 40842097 Get It

Abstract Background Compared to Parkinson's disease, atypical parkinsonian disorders (APD) are characterized by a more rapidly progressive course, often leading to profound disability. Effective communication between clinicians, patients, and care partners is essential to support patient‐centered care and shared decision‐making. However, most neurologists lack formal training in serious illness conversations (SIC). Objective To develop a practical SIC guide tailored to the needs of individuals with APD. Methods Members of the CurePSP Centers of Care Palliative Care Working Group, in collaboration with a SIC education expert (TC), developed a SIC guide for APD. A literature review was conducted, followed by online consensus‐building rounds. Results Applying core communication principles—such as active listening, pausing, naming and validating emotions, assessing understanding, and reframing—can foster alignment between clinicians, patients, and their care partners. Navigating the balance between maintaining hope and providing realistic, anticipatory guidance remains challenging but best achieved by honest, compassionate dialogue. Four practical guides were developed, addressing common and often challenging scenarios: delivering an APD diagnosis, eliciting patient goals in the context of changing clinical status, addressing safety concerns, and discussing quality of life and end‐of‐life considerations. Conclusions Patients and their care partners living with APD benefit greatly from individualized guidance, and honest, empathic communication is a vital part of patient‐centered care. While existing SIC frameworks offer valuable foundations, further research is needed to optimize their adaptation for APD—identifying best timing, specific frameworks, relevant outcome measures, and education strategies to build team‐wide competency.
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer
Ligibel, Jennifer A. , McCall, Linda, Goodwin, Pamela J. , Bernstein, Vanessa , Delahanty, Linda M. , Hahn, Olwen, Hopkins, Judith O. , Irwin, Melinda L. , Minasian, Lori M. , Nebeling, Linda , Neuhouser, Marian L., Paskett, Electra D., Spears, Patricia A. , Stearns, Vered, Thomson, Cynthia A. , Weiss, Anna , White, Julia , Wadden, Thomas A., Hudis, Clifford A. , Ballman, Karla V. , Alfano, Catherine M. , Crane, Tracy E. , Frank, Elizabeth S. , Hershman, Dawn L. , Mayer, Erica L. , Paskett, Electra D. , Winer, Eric P. , Partridge, Ann H. , Carey, Lisa A.

Mayo Clinic

JAMA Oncology | August 21, 2025 | Volume: 11 | Issue: 10 | Pages: 1194

10.1001/jamaoncol.2025.2738 | PMID 40839373 Get It

Importance Obesity is associated with a higher risk of recurrence, mortality, comorbidities, treatment-related adverse effects, and poor quality of life in patients with breast cancer. Scalable interventions are needed to promote weight loss in this population. Objective To evaluate the impact of a remotely delivered weight loss intervention (WLI) on weight change at 1 year in patients with breast cancer and obesity and to explore factors associated with weight change. Design, Setting, and Participants The Breast Cancer Weight Loss trial is a phase 3, randomized clinical trial evaluating the impact of a telephone-based WLI on invasive disease–free survival and other outcomes in women with obesity and early breast cancer at 637 sites across the US and Canada. Participants were enrolled to the study between August 2016 and February 2021. Participants included women with stage II to III, ERBB2 -negative breast cancer and a body mass index (BMI) of 27 or higher. Interventions Participants were randomized to a 2-year, telephone-based WLI plus health education or health education alone control group. Main Outcome and Measures The primary end point for this prespecified secondary analysis was weight change at 1 year. Weight was measured at baseline and 1 year, and changes in weight were compared between groups. Weight change was evaluated with a linear mixed-effects model including treatment group, weight over time, a time-by-group interaction, menopausal status, race and ethnicity, and hormone receptor status. Results A total of 3180 women with breast cancer and BMI of 27 and higher were included in the study; 1591 were randomized to the WLI and 1589 to the control group. At baseline, the mean (SD) age of participants was 53.4 (10.6), and the mean (SD) BMI was 34.4 (5.6). The racial and ethnic breakdown included 406 (12.8%) Black, 231 (7.3%) Hispanic or Latino, 2906 (91.4%) non-Hispanic, and 2555 (80.3%) White participants. WLI participants lost a mean of 4.3 kg (95% CI 3.9-4.6 kg), or 4.7% (95% CI, 4.3%-5.0%) of baseline body weight at 1 year vs control participants, who gained 0.9 kg (95% CI, 0.5-1.3 kg), or 1.0% (95% CI 0.1%-1.4%) of baseline body weight ( P &amp;lt; .001). Participants randomized to WLI experienced significant weight loss (vs control group participants) across demographic and tumor factors. WLI effect differed significantly by menopausal status, with postmenopausal participants having greater weight loss than premenopausal participants, and by race and ethnicity, with Black and Hispanic participants having less weight loss compared to other races and ethnicities. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, a telephone-based WLI induced significant weight loss in patients with breast cancer with overweight and obesity across demographic and treatment factors. Further follow-up of the Breast Cancer Weight Loss trial will evaluate whether the WLI improves disease outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT02750826